Oct 30, 2023 | Appropriateness Solutions, Comparative Effectiveness, Drug costs, MedBen Rx, Pharmacies, Prescription drugs, Research
MedBen Rx’s expanded pharmacy solutions offer a variety of ways to reduce your prescription drug spend… including appropriateness solutions that use clinical-based research to recommend the most effective drugs to your plan members. Comparative...
Oct 16, 2023 | Cost Savings, MedBen Rx, Pharmacies, Prescription drugs, Rx Costs, Savings
From a new report published by the U.S. Department of Health & Human Services: “Over the period from January 2022 to January 2023, more than 4,200 drug products had price increases, of which 46 percent were larger than the rate of inflation. The average drug...
Oct 3, 2023 | MedBen Rx, Pharmacy Benefits Manager (PBM), Rebates, White paper
In their continuing quest for bigger profits, major pharmacy benefit managers (PBMs) have adapted a new tactic: clever wordplay. What was once known as a “rebate” – a partial refund of the drug payment back to the plan – now goes by a variety of other...
Sep 29, 2023 | Announcements, Biosimilar, Humira, MedBen Rx, News, Perigon Pharmacy 360, Ventegra
Here’s some cost-saving news for MedBen Rx clients who use Ventegra as their processor. On July 1, 2023, biosimilar products were released for the popular and expensive anti-inflammatory therapy, Humira. A 30-day supply of Humira, which is used to treat a variety of...
Sep 18, 2023 | Announcements, Diabetes, MedBen Rx, Ozempic, Weight loss
Important information for MedBen Rx clients using the Ventegra formulary: Effective October 1, an appropriate ICD-10 diagnosis code for type 2 diabetes will be required for certain Ozempic prescriptions and all other GLP-1 class medications. Ozempic and other GLP-1...
Sep 5, 2023 | Access solutions, MedBen Rx, Reporting, Rx Costs, Savings, Specialty Drugs, Surveys
A new survey by International Foundation of Employee Benefit Plans found employers expect plan costs to increase seven percent in 2024. As to why, they gave a range of answers, with the top four reasons representing 71 percent of responses (see chart below). As it...
